{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:11:54Z","timestamp":1792725114100,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clml.2025.06.014","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T10:19:11Z","timestamp":1750587551000},"page":"897-909.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Hans C.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Bumma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1741-2795","authenticated-orcid":false,"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-8479","authenticated-orcid":false,"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0835-800X","authenticated-orcid":false,"given":"Viviana","family":"Garc\u00eda-Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Fillbrunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4418-7263","authenticated-orcid":false,"given":"Matthew","family":"Mattera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-4078","authenticated-orcid":false,"given":"Timothy J.","family":"Inocencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Bergrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4217-0118","authenticated-orcid":false,"given":"James","family":"Harnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito","family":"Roccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2897-9810","authenticated-orcid":false,"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Rodriguez","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2025.06.014_bib0001","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/leu.2017.122","article-title":"Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes","volume":"31","author":"Hari","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.06.014_bib0002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/2040620716667275","article-title":"A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma","volume":"7","author":"Franken","year":"2016","journal-title":"Ther Adv Hematol"},{"issue":"Supplement 16","key":"10.1016\/j.clml.2025.06.014_bib0003","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1200\/JCO.2024.42.16_suppl.7561","article-title":"Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Kumar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.06.014_bib0004","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"12","key":"10.1016\/j.clml.2025.06.014_bib0005","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.clml.2025.06.014_bib0006","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.014_bib0007","unstructured":"US Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma. Accessed November 19, 2024, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0008","unstructured":"European Medicines Agency. First cell-based gene therapy to treat adult patients with multiple myeloma. Accessed November 19, 2024, https:\/\/www.ema.europa.eu\/en\/news\/first-cell-based-gene-therapy-treat-adult-patients-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0009","unstructured":"US Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Accessed November 19, 2024, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0010","unstructured":"European Medicines Agency. New gene therapy to treat adult patients with multiple myeloma. Accessed November 19, 2024, https:\/\/www.ema.europa.eu\/en\/news\/new-gene-therapy-treat-adult-patients-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0011","unstructured":"US Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Accessed November 19, 2024, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0012","unstructured":"European Medicines Agency. New medicine for multiple myeloma patients with limited treatment options. Accessed November 19, 2024, https:\/\/www.ema.europa.eu\/en\/news\/new-medicine-multiple-myeloma-patients-limited-treatment-options."},{"key":"10.1016\/j.clml.2025.06.014_bib0013","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. Accessed November 19, 2024, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0014","unstructured":"European Medicines Agency. New treatment option for heavily pre-treated multiple myeloma patients. Accessed November 19, 2024, https:\/\/www.ema.europa.eu\/en\/news\/new-treatment-option-heavily-pre-treated-multiple-myeloma-patients."},{"key":"10.1016\/j.clml.2025.06.014_bib0015","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to talquetamab-tg vs for relapsed or refractory multiple myeloma. Accessed November 19, 2024, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0016","unstructured":"Johnson & Johnson. European Commission approves TALVEY\u24c7xsy (talquetamab), Janssen\u2019s novel bispecific therapy for the treatment of patients with relapsed and refractory multiple myeloma. Accessed November 19, 2024, https:\/\/www.jnj.com\/media-center\/press-releases\/european-commission-approves-talvey-talquetamab-janssens-novel-bispecific-therapy-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma."},{"key":"10.1016\/j.clml.2025.06.014_bib0017","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to selinexor for multiple myeloma. Accessed November 19, 2024, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-selinexor-multiple-myeloma."},{"issue":"22","key":"10.1016\/j.clml.2025.06.014_bib0018","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.06.014_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0266462319000333","article-title":"Population adjustment methods for indirect comparisons: a review of National Institute for Health and Care Excellence Technology appraisals","volume":"35","author":"Phillippo","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"10","key":"10.1016\/j.clml.2025.06.014_bib0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.clml.2025.06.014_bib0021","doi-asserted-by":"crossref","first-page":"A48","DOI":"10.1016\/j.jval.2013.03.271","article-title":"Matching-adjusted indirect comparisons: a simulation study of statistical performance","volume":"16","author":"Signorovitch","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2025.06.014_bib0022","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams K, Welton N. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Accessed November 19, 2024, https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf."},{"issue":"6","key":"10.1016\/j.clml.2025.06.014_bib0023","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 2","key":"10.1016\/j.clml.2025.06.014_bib0024","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/S2152-2650(23)01900-6","article-title":"P-282 ranking importance of prognostic factors for relapsed\/refractory multiple myeloma (RRMM): international physician panel consensus following a systematic review of the literature","volume":"23","author":"Kumar","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 3","key":"10.1016\/j.clml.2025.06.014_bib0025","article-title":"PB2090: systematic literature review of prognostic factors for relapsed\/refractory multiple myeloma","volume":"7","author":"Kumar","year":"2023","journal-title":"Hemasphere"},{"issue":"25","key":"10.1016\/j.clml.2025.06.014_bib0026","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"Supplement 15","key":"10.1016\/j.clml.2025.06.014_bib0027","doi-asserted-by":"crossref","first-page":"8047","DOI":"10.1200\/JCO.2021.39.15_suppl.8047","article-title":"Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and\/or refractory multiple myeloma","volume":"39","author":"Girgis","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.014_bib0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2025.06.014_bib0029","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams K, Welton N. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision Support Unit. 2016. https:\/\/sheffield.ac.uk\/nice-dsu\/tsds\/population-adjusted. Access date be Nov 16."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.06.014_bib0030","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-208776","article-title":"3265 Characterization of linvoseltamab\u2019s BCMA binding epitope and efficacy against BCMA mutations in relapsed\/refractory multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.014_bib0031","unstructured":"US Food and Drug Administration. Project Optimus - reforming the dose optimization and dose selection paradigm in oncology. Accessed November 19, 2024, https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-optimus."},{"issue":"5","key":"10.1016\/j.clml.2025.06.014_bib0032","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma","volume":"65","author":"Mol","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.clml.2025.06.014_bib0033","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41408-021-00588-z","article-title":"Impact of COVID-19 in patients with multiple myeloma based on a global data network","volume":"11","author":"Martinez-Lopez","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.clml.2025.06.014_bib0034","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11523-021-00821-6","article-title":"Baseline and changes in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among patients with relapsed\/refractory multiple myeloma starting new therapy","volume":"16","author":"Bujarski","year":"2021","journal-title":"Target Oncol"},{"issue":"1611171","key":"10.1016\/j.clml.2025.06.014_bib0035","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:10:52Z","timestamp":1763773852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2152265025002228"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.014","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}